Romidepsin
Small molecule
Also known as FK228
Evidence outlook
Approved: Cutaneous T-Cell Lymphoma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Also approved (1)
- Treatment of relapsed or refractory peripheral T- cell lymphoma
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00106431 NCT00106431 · Cutaneous T-Cell Lymphoma Registry: NCT00106431 | 2 | The Percent of Patients (Pts) With Objective Disease Response (6 months) 2008-06-01 | The Percent of Patients (Pts) With Objective Disease Response (6 months): Romidepsin 34 Percent of participants | not yet graded | link ↗ |
View 1 more trial
NCT00007345 NCT00007345 · Cutaneous T-Cell Lymphoma Registry: NCT00007345 | 2 | Number of Participants With a Response (up to 56.5 days); Duration of Response (DOR) (up to 127 months) 2015-01-26 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (2)
What this study did
What this study did
Phase 2 (35)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (20)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (37)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Used as active comparator (3)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (3)
What this study did
What this study did
What this study did
Competitive landscape
Other HDAC drugs
Givinostat, Vorinostat, Panobinostat, Chidamide, Purinostat Mesylate. Compare all 6 HDAC drugs
6 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Cutaneous T-Cell Lymphoma: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Romidepsin: this drug | Approved | Small molecule | HDAC | not yet graded | No reviewed efficacy summary in this indication | |
| Brentuximab Vedotin | Approved | Antibody–drug conjugate | Anti-CD30 antibody-drug conjugate | Partial signal | NCT01578499: Percentage of Participants Achieving an Objective Response That Lasts at Least 4 Months (ORR4) (Each Cycle until disease progression, death End of treatment (Median overall follow-up 38.8 months)): Brentuximab Vedotin 54.7 percentage of participants (95% CI 42.5 to 66.9) | Methotrexate or Bexarotene 12.5 percentage of participants (95% CI 4.4 to 20.6) | |
| Givinostat | Approved(overall) | Small molecule | HDAC | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Vorinostat | Approved | Small molecule | HDAC | not yet graded | No reviewed efficacy summary in this indication | |
| Panobinostat | US approval withdrawn(overall) | Small molecule | HDAC | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Chidamide | Phase 3(overall) | Small molecule | HDAC | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Purinostat Mesylate | Phase 3(overall) | Small molecule | HDAC | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Lacutamab | Phase 2 | Monoclonal antibody | KIR3DL2 | not yet graded | No reviewed efficacy summary in this indication | |
| REC-2282 | Discontinued | Small molecule | HDAC | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Romidepsin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent